What are the etiology, pathogenesis, clinical features, management, complications, and prognosis of multiple sclerosis?

Multiple Sclerosis: Comprehensive Overview

Etiology

Multiple sclerosis has a complex, multifactorial etiology involving genetic predisposition, immunological dysregulation, and environmental triggers, though the precise cause remains unknown 1, 2.

The disease involves:

• Genetic susceptibility - familial clustering suggests hereditary components
• Environmental factors - including viral infections (particularly Epstein-Barr virus), vitamin D deficiency, and geographic latitude
• Immunological factors - autoreactive T cells and B cells targeting CNS myelin components 3, 4

Research increasingly points to Epstein-Barr virus infection as a significant environmental trigger, along with alterations in the microbiome-gut-brain axis 4.

Pathogenesis

MS is a chronic inflammatory and autoimmune disease of the central nervous system characterized by widespread focal demyelination, variable axonal injury, and progressive neuronal damage 1.

The pathophysiological cascade involves:

• Immune dysregulation: Autoreactive T cells and B cells cross the blood-brain barrier and attack myelin sheaths
• Inflammatory infiltration: Perivenular inflammatory cell infiltrates with cytokine release
• Demyelination: Destruction of myelin sheaths disrupts nerve impulse conduction
• Axonal transection and neuronal degeneration: Progressive loss of neuronal function beyond demyelination
• Gliosis and scarring: Formation of characteristic sclerotic plaques 5, 2

Both white matter and gray matter are affected, with multifocal lesions throughout the CNS 5. The pathology is heterogeneous, involving complex T-cell and B-cell mechanisms, oxidative damage, mitochondrial dysfunction, and blood-brain barrier disruption 4, 2.

Clinical Features

Disease Subtypes

Two main clinical forms exist 1:

1. Relapsing-Remitting MS (RRMS) - 85% of cases

   • Acute inflammatory relapses followed by remission phases
   • Nerve conduction affected during relapses but improves with healing
   • Over time, relapses cause cumulative damage with progressive neuronal loss

2. Primary-Progressive MS (PPMS) - 15% of cases

   • Progressive neurological deterioration from onset without distinct relapses/remissions
   • Characterized by continuous neurodegeneration rather than inflammatory attacks

Clinical Presentation

MS typically begins with a clinically isolated syndrome (CIS) - an acute episode of neurological disturbance 6. Common manifestations include:

• Motor dysfunction: Weakness, spasticity, tremor
• Sensory deficits: Paresthesias, pain, sensory loss
• Visual disturbances: Optic neuritis, diplopia, poor sight
• Cognitive impairment: Memory problems, reduced cognition
• Autonomic dysfunction: Bladder/bowel sphincter disorders, erectile dysfunction
• Fatigue: Profound and disabling
• Dysphagia: Swallowing difficulties
• Mood disorders: Depression, anxiety 1, 6

Weight loss, malnutrition, and cachexia are well-recognized features due to reduced mobility, fatigue, inappropriate diet, physical difficulty eating/drinking, poor appetite, and dysphagia 1.

Diagnosis

Diagnostic Framework

Diagnosis requires objective evidence of dissemination in time and space of CNS lesions typical of MS, with exclusion of alternative explanations 7. The McDonald criteria (revised multiple times, most recently in 2024) guide diagnosis 8, 7.

Key Diagnostic Components

MRI is the most sensitive and specific diagnostic tool 7:

• Brain MRI findings: Multiple T2-hyperintense lesions in characteristic locations

  • Periventricular lesions (at least 1)
  • Juxtacortical/cortical lesions (at least 1)
  • Infratentorial lesions (at least 1)
  • Spinal cord lesions (at least 1) 8

• Central Vein Sign (CVS): More than 40% of lesions showing CVS correctly identifies nearly all MS patients (Select 6 rule) 8

• Paramagnetic Rim Lesions (PRL): Presence of at least 4 PRL associated with greater disability 8

• Gadolinium enhancement: Indicates active inflammation and helps establish dissemination in time

Cerebrospinal fluid analysis adds information about inflammation and immunological disturbance 7:

• Oligoclonal bands (OCB) - particularly useful when imaging criteria not fully met
• Elevated IgG index
• Possible neutrophilic pleocytosis or WCC >50/μl 9

Visual evoked potentials (VEP) provide additional support when MRI abnormalities are few or less specific 7.

Diagnostic Categories

Following evaluation, patients are classified as:

• MS - meeting full diagnostic criteria
• Possible MS - appropriate clinical presentation but not meeting all criteria
• Not MS - alternative diagnosis established 7

Management

Disease-Modifying Therapies (DMTs)

First-line DMTs for relapsing-remitting MS include interferon-β and glatiramer acetate 6. The therapeutic landscape has expanded significantly:

Available DMT classes 10, 6:

• Interferons (interferon-β)
• Glatiramer acetate
• Oral immunomodulators: Fingolimod, dimethyl fumarate, teriflunomide, cladribine
• Monoclonal antibodies: Natalizumab, alemtuzumab, ocrelizumab, ofatumumab, rituximab

Each targets different immune response components with unique mechanisms and safety profiles 3.

Acute Relapse Management

First-line treatment for relapses is intravenous methylprednisolone for 3 days 6.

Autologous Haematopoietic Stem Cell Transplantation (AHSCT)

AHSCT is emerging as a treatment option for highly active relapsing MS 10. Eligibility criteria from recent trials include:

• Age 18-55 years
• EDSS score 0.0-6.0
• Active disease despite DMT (≥1 relapse and MRI activity in previous 12 months)
• Prior DMT failure required

Conditioning regimens include cyclophosphamide + ATG or BEAM + ATG 10.

Symptomatic Management

Specific symptoms require targeted pharmacological and non-pharmacological interventions 6:

• Spasticity: Antispasmodic agents, physical therapy
• Fatigue: Energy conservation strategies, possible pharmacotherapy
• Pain and paresthesias: Neuropathic pain medications
• Bladder/bowel dysfunction: Anticholinergics, intermittent catheterization, bowel programs
• Erectile dysfunction: PDE5 inhibitors
• Depression/anxiety: Antidepressants, psychological support
• Tremor: Beta-blockers, anticonvulsants
• Dysphagia: Speech therapy, dietary modifications

Allied health consultation and continence strategies are essential components 6.

Nutritional Considerations

A diet lower in saturated fat and higher in polyunsaturated fatty acids from food sources is suggested for MS prevention (Grade B recommendation) 1.

Omega-3 fatty acid supplementation is NOT recommended for prevention (Grade 0 recommendation) 1.

Monitoring and Surveillance

Regular brain MRI is essential for monitoring disease progression 11:

• Routine follow-up: At least annually using contrast-enhanced T1-weighted and T2-weighted/FLAIR sequences
• Enhanced pharmacovigilance: Every 3-4 months for patients at high risk of complications

For natalizumab-treated patients at high risk of progressive multifocal leukoencephalopathy (PML) (JCV seropositive, treatment duration ≥18 months): brain MRI screening every 3-4 months using FLAIR, T2-weighted, and diffusion-weighted imaging 11.

Patients switching DMDs require enhanced monitoring - brain MRI every 3-4 months for up to 12 months to detect opportunistic infections and disease reactivation 11.

Complications

Treatment-Related Complications

Progressive multifocal leukoencephalopathy (PML) is a serious opportunistic infection risk with:

• Natalizumab (highest risk)
• Alemtuzumab
• Rituximab
• Dimethyl fumarate 11

Carry-over opportunistic infections can occur when switching therapies, particularly from natalizumab to fingolimod, alemtuzumab, or dimethyl fumarate 11.

Disease-Related Complications

Progressive disability accumulation includes:

• Motor impairment and wheelchair dependence
• Cognitive decline
• Visual impairment
• Sphincter dysfunction
• Chronic pain
• Severe fatigue
• Malnutrition and cachexia 1, 3

Vascular complications: Accelerated vascular aging and increased atherosclerosis risk, independent of traditional cardiovascular risk factors 4.

Autonomic dysfunction develops secondary to disease progression 4.

Prognosis

Prognosis varies substantially across individual patients 12.

Favorable Prognostic Indicators

• Younger age at onset
• Female sex
• Relapsing-remitting course
• Complete recovery from initial attacks
• Longer intervals between relapses
• Sensory symptoms at onset

Unfavorable Prognostic Indicators

Initial brain MRI features predicting poor long-term disability 8:

• Large number (>20) and volume of T2-weighted lesions
• Brainstem, cortical, or spinal cord lesions
• Multiple gadolinium-enhancing lesions
• Reduced whole brain volume or ventricular expansion
• Regional brain atrophy (corpus callosum, thalamus, brainstem)
• Presence of ≥4 paramagnetic rim lesions
• High proportion of lesions with central vein sign

Short-term follow-up MRI findings: New lesions in spinal cord and brainstem strongly predict long-term disability 8.

Clinical factors:

• Primary-progressive course (15-20% of patients)
• Motor symptoms at onset
• Frequent early relapses
• Incomplete recovery from relapses
• Early disability accumulation

After 10 years, relapsing-remitting MS may transition to secondary progressive MS with continuous disability accumulation without distinct relapses 6.

MS patients typically have a long life span, though healthcare utilization increases over time, placing substantial burden on patients, caregivers, and society 5.